Madzikwa matter postponed

The matter of NatPham’s boss Newman Madzikwa who is facing charges of criminal abuse of office has been postponed as the State needs more time to transcribe the new evidence that is set to be heard in court.

0
215
The matter of NatPham’s boss Newman Madzikwa who is facing charges of criminal abuse of office has been postponed as the State needs more time to transcribe the new evidence that is set to be heard in court.
The matter of NatPham’s boss Newman Madzikwa who is facing charges of criminal abuse of office has been postponed as the State needs more time to transcribe the new evidence that is set to be heard in court.

The matter of NatPham’s boss Newman Madzikwa who is facing charges of criminal abuse of office has been postponed as the State needs more time to transcribe the new evidence that is set to be heard in court.

The matter was on halt following revelations by the State led by Zivanai Macharaga that he had stumbled upon new evidence which might help exonerate the boss in the matter before court.

Macharaga told the court they are almost done with transcribing and the matter was remanded to April 22.

This new found evidence is in the form of a recording which was recorded during a meeting in which the charges are based and the minutes which would have substituted this recording had not been brought in court as they were not signed for nor authenticated thereby inadmissible in court.

The matter is being heard before Regional Magistrate Hosea Mujaya.

He evoked Section 232 on the Criminal Procedure and Evidence Act which provides for him to call any witness to testify.

Madzikwa is facing two counts of criminal abuse of office. He was allegedly appointed as the acting manager of NatPharm fraudulently by Dr Parirenyatwa through a directive to the NatPharm board without following procedure.

It is the State’s case that Madzikwa, contrary to the requirements, directed his financial manager Roland Mlalazi in a management meeting held on September 3, to effect a 11 percent hike of the handling from four to 15 percent which could have potentially caused price hikes of basic drugs to consumers.

In the second count, Madzikwa is alleged to have acted in contrary with his duties by handpicking a Danish company called MissionPharma to supply medicines worth $10million without going to tender.

Madzikwa is currently out on $200 bail.